A new study has found that the fynbos plant Cyclopia could help stop the development of breast cancer.
Stellenbosch University said in a statement that researcher, Dr Koch Visser, studied the relationship between Cyclopia, which is used to make honey bush tea, and breast cancer cells, News 24 reported.
Visser found that Cyclopia extracts prevent the estrogen-induced growth of breast cancer cells by targeting and inhibiting estrogen receptor subtypes that promote the growth of these cells.
Visser said that there's a possibility that this research could offer respite to women who may be diagnosed with breast cancer in future, especially considering the global need to better understand the development and progression of this disease in order to treat it effectively.
While other breast cancer drugs appeared to increase the risk of cancer of the uterus, Visser's study suggested that Cyclopia extracts did not have this effect.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
